Research says scrapped Alzheimer’s drug Adcanumab works at highest doses
SAN DIEGO (KUSI) – A once-scrapped Alzheimer’s drug may work after all. New analysis suggests that, at the highest doses, Aducanumab slowed mental decline, the drug developer claims.
Aducanumab is an anti-amyloid antibody that selectively binds to beta-amyloid to reduce the formation of plaques.
Dr. Lisa Delano-Wood, Board member of the Alzheimer’s Association, was in studio to tell us more about it.
For more info on Clinical Trials on Alzheimer’s Disease in San Diego, visit www.ctad-alzheimer.com.